Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends multiple myeloma drugs

The National Institute for Health and Clinical Excellence has issued draft guidance recommending bortezomib and thalidomide for multiple myeloma

The National Institute for Health and Clinical Excellence (NICE) has issued draft guidance recommending bortezomib and thalidomide for multiple myeloma (MM) – a cancer that affects plasma cells, a type of white blood cell, in bone marrow.

Thalidomide, sold under the brand name Thalidomide by Celgene, is recommended for the first-line treatment of MM in patients for whom high-dose chemotherapy with stem cell transplantation is not an option. The drug would be used in combination with an alkylating agent and a corticosteroid.

Bortezomib, marketed as Velcade by Janssen-Cilag in the UK, is similarly recommended in combination with an alkylating agent and a corticosteroid if it is inadvisable for a patient to use thalidomide.

Both treatments were considered to be equally effective by the NICE Appraisal Committee, though thalidomide was seen as a more cost-effective option.

Dr Carole Longson, director of the Health Technology Evaluation Centre at NICE said: "The evidence clearly showed that both thalidomide and bortezomib regimens are more effective at delaying disease progression and improving patients' life expectancy than the current treatment of an alkylating agent and corticosteroid alone."

MM is the second most common haematological cancer in the UK, with around 3,600 diagnoses a year in England and Wales. There are thought to be currently between 10,000 and 15,000 people living with the disease in the UK.

Most cases of the disease are diagnosed in elderly patients, with many unable to withstand intensive treatment, such as high-dose chemotherapy with stem cell transplantation, because of their age or other health problems.

Final guidance for both treatments is expected to be published in September 2010.

26th August 2010

From: Healthcare

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics